KHKristen Hong

Kristen Hong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kristen Hong has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Anna Schwendeman

    Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI, USA

    4 shared publications
  • Hongliang He

    State Key Laboratory of Digital Medical Engineering, Jiangsu Key Laboratory for Biomaterials and Devices, School of Biological Sciences & Medical Engineering, Southeast University, Nanjing 210009, People's Republic of China

    2 shared publications
  • Huilun Wang

    Department of Internal Medicine, Frankel Cardiovascular Center (Y. Liu, H.W., Y.C., Ying Zhao, Y. Luo, G.Z., Yang Zhao, Y.D., W.M., H. Liu, X.W., Z.W., J.Z., L.C., Y.E.C., Y.G.), University of Michigan Medical Center, Ann Arbor

    2 shared publications
  • Jifeng Zhang

    Center for Advanced Models for Translational Sciences and Therapeutics, Department of Internal Medicine, University of Michigan Medical School

    2 shared publications
  • Lin Chang

    Department of Internal Medicine, Frankel Cardiovascular Center (Y. Liu, H.W., Y.C., Ying Zhao, Y. Luo, G.Z., Yang Zhao, Y.D., W.M., H. Liu, X.W., Z.W., J.Z., L.C., Y.E.C., Y.G.), University of Michigan Medical Center, Ann Arbor

    2 shared publications
  • Lisha Liu

    Department of Pharmaceutical Sciences, College of Pharmacy University of Michigan Ann Arbor Michigan USA

    2 shared publications

Latest Publications

  • Restoring Vascular Smooth Muscle Cell Mitochondrial Function Attenuates Abdominal Aortic Aneurysm in Mice

    by Yaozhong Liu, Minzhi Yu, Huilun Wang, Kristen Hong Dorsey, Yalun Cheng, Ying Zhao, Yonghong Luo, Guizhen Zhao, Yang Zhao, Haocheng Lu, et al.

    BACKGROUND: Abdominal aortic aneurysm (AAA) is a complex vascular pathology without pharmaceutical interventions. This study aimed to evaluate whether restoring vascular smooth muscle cell (VSMC) mitochondrial function could prevent AAA development. METHODS: Ang II (angiotensin II)–induced AAA was established in Ldlr -deficient mice, and the gene expression profiles in abdominal aortic tissues exhibiting varying degrees of severity were analyzed. Synthetic high-density lipoprotein (sHDL) formulated with Apoa1 mimetic peptide and phospholipids was evaluated for the protective effects on VSMC mitochondria. The therapeutic efficacy of sHDL was further investigated in Ang II–infusion and PPE (porcine pancreatic elastase)-induced AAA models. RESULTS: VSMC mitochondrial damage intensified gradually during AAA development, which was confirmed in distinct AAA animal models and human tissues. sHDL accumulated in the aneurysmatic lesions and restored mitochondrial DNA levels and the expression of genes related to oxidative phosphorylation following Ang II infusion. In mouse primary VSMCs, sHDL maintained mitochondrial homeostasis by suppressing the upregulation of DRP1 (dynamin-related protein 1), a protein involved in mitochondrial fission, reducing the generation of reactive oxygen species, preventing the loss of mitochondrial membrane potential, and preserving mitochondrial respiratory capacity. Administration of sHDL decreased Ang II–induced AAA incidence (control versus treatment, 76% versus 40%; P <0.05) and maximum aortic diameters. The protective effects of sHDL were further validated in the PPE model, with reductions observed in maximum aortic diameters and aortic mitochondrial DNA loss. Post-Ang II infusion, administration of sHDL improved VSMC mitochondrial function and suppressed aneurysm growth in Apoe-deficient mice. Human AAA is characterized by mitochondrial dysfunction, and liver-derived HDL (high-density lipoprotein) components play a pivotal role in regulating gene expression in aortic tissues. CONCLUSIONS: VSMC mitochondrial damage is a pivotal factor in the development of AAA. The utilization of sHDL nanoparticles represents a promising novel therapeutic approach for AAA, aimed at restoring VSMC mitochondrial function.


  • Open Access

    Phospholipid nanoparticles: Therapeutic potentials against atherosclerosis via reducing cholesterol crystals and inhibiting inflammation

    by Yonghong Luo, Yanhong Guo, Huilun Wang, Minzhi Yu, Kristen Hong, Dan Li, Ruiting Li, Bo Wen, Die Hu, Lin Chang, et al.


  • Artificial high‐density lipoprotein‐mimicking nanotherapeutics for the treatment of cardiovascular diseases

    by Hongliang He, Kristen Hong, Lisha Liu, Anna Schwendeman

    Despite the ability of current efficacious low‐density lipoprotein‐cholesterol–lowering therapies to reduce total cardiovascular disease (CVD) risks, CVD still poses major risks for morbidity and mortality to the general population. Because of the pleiotropic endothelial protective effects of high‐density lipoproteins (HDL), the direct infusion of reconstituted HDL (rHDL) products, including MDCO‐216, CER001, and CSL112, have been tested in clinical trials to determine whether direct infusion of rHDL can reduce coronary events in CVD patients. In addition to these rHDL products, in the past two decades, there has been an increased focused on designing artificial HDL‐mimicking nanotherapeutics to produce complementary therapeutic strategies for CVD patients beyond lowering of atherogenic lipoproteins. Although recent reviews have comprehensively discussed the developments of artificial HDL‐mimicking nanoparticles as therapeutics for CVD, there has been little assessment of “plain” or “drug‐free” HDL‐mimicking nanoparticles as therapeutics alone. In this review, we will summarize the clinical outcomes of rHDL products, examine recent advances in other types of artificial HDL‐mimicking nanotherapeutics, including polymeric nanoparticles, cyclodextrins, micelles, metal nanoparticles, and so on; and potential new approaches for future CVD interventions. Moreover, success stories, lessons, and interpretations of the utility and functionality of these HDL‐mimicking nanotherapeutics will be an integral part of this article.This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Cardiovascular Disease


  • Open Access

    Synthetic high-density lipoproteins loaded with an antiplatelet drug for efficient inhibition of thrombosis in mice

    by Hongliang He, Reheman Adili, Lisha Liu, Kristen Hong, Michael Holinstat, Anna Schwendeman

    SHDL is a promising antithrombotic agent delivery system due to its antithrombotic effect itself and improved drug delivery.


  • Neuronal uptake transporters contribute to oxaliplatin neurotoxicity in mice

    by Kevin M. Huang, Alix F. Leblanc, Muhammad Erfan Uddin, Ji Young Kim, Mingqing Chen, Eric D. Eisenmann, Alice A. Gibson, Yang Li, Kristen W. Hong, Duncan DiGiacomo, et al.

    Peripheral neurotoxicity is a debilitating condition that afflicts up to 90% of patients with colorectal cancer receiving oxaliplatin-containing therapy. Although emerging evidence has highlighted the importance of various solute carriers to the toxicity of anticancer drugs, the contribution of these proteins to oxaliplatin-induced peripheral neurotoxicity remains controversial. Among candidate transporters investigated in genetically engineered mouse models, we provide evidence for a critical role of the organic cation transporter 2 (OCT2) in satellite glial cells in oxaliplatin-induced neurotoxicity, and demonstrate that targeting OCT2 using genetic and pharmacological approaches ameliorates acute and chronic forms of neurotoxicity. The relevance of this transport system was verified in transporter-deficient rats as a secondary model organism, and translational significance of preventive strategies was demonstrated in preclinical models of colorectal cancer. These studies suggest that pharmacological targeting of OCT2 could be exploited to afford neuroprotection in cancer patients requiring treatment with oxaliplatin.